Article Text

other Versions

Download PDFPDF
22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report
  1. Zoia Razumova1,
  2. Nicolò Bizzarri2,
  3. Andrei Pletnev3,
  4. Charlampos Theofanakis4,
  5. Ilker Selcuk5,
  6. Elzbieta van der Steen-Banasik6,
  7. Antonio Gonzalez Martin7,8 and
  8. Jan Persson9,10
  1. 1Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
  2. 2UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Policlinico Agostino Gemelli IRCCS, Rome, Italy
  3. 3Department of Gynecology and Obstetrics, Faculty of Medicine and Health Sciences, University of Zielona Góra, Zielona Gora, Poland
  4. 4Department of Gynaecological Oncology, General Hospital of Athens Alexandra, Athens, Greece
  5. 5Gynecologic Oncology, Ankara City Hospital, Ankara, Turkey
  6. 6Radation Oncology, Radiotherapy Group, Arnhem, Gelderland, The Netherlands
  7. 7Department of Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain
  8. 8Centre for Applied Medical Research (CIMA), Pamplona, Spain
  9. 9Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, Skåne University Hospital, Lund, Sweden
  10. 10Department of Clinical Sciences, Lund University Faculty of Medicine, Lund, Sweden
  1. Correspondence to Dr Zoia Razumova, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; zoia.razumova{at}ki.se

Abstract

This is a report from the 22nd Meeting of the European Society of Gynaecological Oncology, held October 23–25, 2021. The 3-day event offered an educational experience covering the major scientific and clinical advances in gynecological oncology. The Congress program included different session formats, including guidelines updates and state-of-the-art lectures. This article provides an overview of the main Congress activities as well as of the most important studies that were presented at the event for the first time.

  • cervical cancer
  • ovarian cancer
  • uterine cancer
  • vulvar and vaginal cancer

Data availability statement

No data are available.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Twitter @ilkerselcukmd

  • Contributors ZR: conceptualization, data curation, methodology, writing original draft, review, and editing. NB: conceptualization, data curation, methodology, writing original draft. AP: conceptualization, data curation, methodology, writing original draft. CT: conceptualization, data curation, methodology, writing original draft. IS: conceptualization, data curation, methodology, writing original draft. EMVDS-B: conceptualization, methodology, review, editing. AGM: conceptualization, methodology, review, editing. JP: conceptualization, methodology, review, editing.

  • Funding The work was funded through the ENYGO budget grant that was provided by ESGO.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.